Literature DB >> 9088880

Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase.

F M Sherif1, A M Tawati, S S Ahmed, S I Sharif.   

Abstract

Neuronal dysfunction is the neurobiological basis for alcoholic behaviour, and ethanol craving seems related to hypofunction of the GABA-ergic activity. Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS). In several studies, GABA has been shown to be an important target of ethanol in the CNS, partly, as a consequence of damage to membrane-bound enzymes and receptors. GABA is involved in mediating pre- and post-synaptic inhibition of neuronal activity. It is speculated that the initial excitatory effects of ethanol may be due to inhibition of GABA-ergic activity whereas the sedative effects of the higher doses may be mediated by the activation of this inhibitory system. In the CNS, GABA is synthesised from glutamic acid by the enzyme glutamate decarboxylase (GAD) and catabolized into succinic semialdehyde by the enzyme GABA-transaminase (GABA-T), which are pyridoxal phosphate (PLP) dependent enzymes. Platelet GABA-T was characterized as being similar to central GABA-T. Inhibition of GABA-T with certain potent and selective compounds markedly increases the levels of brain GABA. Experimentally, acute ethanol treatment does not alter GABA-T activity whereas chronic treatment produces an increase in the activity, though, with some reservations since a bimodal effect has been found in chronically ethanol-treated rats. Thus, as it will be discussed below, it may be suggested that GABA-T inhibitors (e.g. vigabatrin) could have a potential role in the treatment of alcoholism and in some of the problems of ethanol withdrawal and of other drugs of abuse. Related studies on metabolism and concentrations of GABA are also promising and show a greater increase in our understanding of the aetiology and treatment of ethanol dependence and withdrawal. In general, this article also reviews both the animal and clinical observations in the field of alcoholism with regard to the GABA system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088880     DOI: 10.1016/s0924-977x(96)00383-5

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

1.  Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.

Authors:  Rosane Gomez; Kevin L Behar; June Watzl; Stuart A Weinzimer; Barbara Gulanski; Gerard Sanacora; Julia Koretski; Elizabeth Guidone; Lihong Jiang; Ismene L Petrakis; Brian Pittman; John H Krystal; Graeme F Mason
Journal:  Biol Psychiatry       Date:  2011-08-19       Impact factor: 13.382

2.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

Review 3.  Alcohol consumption and hypertension.

Authors:  Michael Huntgeburth; Henrik Ten Freyhaus; Stephan Rosenkranz
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

4.  Single-dose ethanol intoxication causes acute and lasting neuronal changes in the brain.

Authors:  Johannes Knabbe; Jil Protzmann; Niklas Schneider; Michael Berger; Dominik Dannehl; Shoupeng Wei; Christopher Strahle; Michèle Tegtmeier; Astha Jaiswal; Hongwei Zheng; Marcus Krüger; Karl Rohr; Rainer Spanagel; Ainhoa Bilbao; Maren Engelhardt; Henrike Scholz; Sidney B Cambridge
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-14       Impact factor: 12.779

5.  Suicidal behavior and alcohol abuse.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giovanni Dominici; Stefano Ferracuti; Giorgio D Kotzalidis; Giulia Serra; Paolo Girardi; Luigi Janiri; Roberto Tatarelli; Leo Sher; David Lester
Journal:  Int J Environ Res Public Health       Date:  2010-03-29       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.